Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer

Urology
Ashesh B JaniRalph R Weichselbaum

Abstract

To report a single-institution experience and analysis of the role of supplemental external beam radiotherapy (EBRT) with brachytherapy. EBRT is often used in addition to low-dose-rate brachytherapy in the treatment of prostate cancer, particularly for disease with adverse features. A cohort of 189 consecutive patients, who had undergone low-dose-rate brachytherapy at our institution and who had demographic, disease, and treatment information and a minimum of 2 years of follow-up available, constituted the study group. This cohort was divided into two major groups according to the use of supplemental EBRT. Using two successive prostate-specific antigen rises greater than 1 ng/mL as the definition of failure, biochemical failure-free survival curves were constructed for the EBRT and no-EBRT groups and compared using the log-rank test. Additionally, a multivariate analysis of all major disease and treatment factors was performed using the Cox proportional hazards model. Despite the greater proportion of adverse disease factors in the EBRT group, the 5-year biochemical failure-free survival rate in the EBRT versus no-EBRT groups was 80% versus 59%, respectively (P < 0.01). On multivariate analysis, the only factor reaching signifi...Continue Reading

References

Dec 24, 1998·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·C B SawR Nath
May 11, 1999·JAMA : the Journal of the American Medical Association·W U ShipleyC D Smith
Jul 1, 1999·International Journal of Radiation Oncology, Biology, Physics·S NagR Nath
Mar 8, 2000·International Journal of Radiation Oncology, Biology, Physics·J C BlaskoW Cavanagh
Dec 6, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J C BlaskoW Cavanagh
Aug 23, 2001·International Journal of Radiation Oncology, Biology, Physics·P D GrimmW Cavanagh
Jan 29, 2002·Seminars in Radiation Oncology·John C BlaskoWilliam Cavanagh
Mar 28, 2003·Lancet·Ashesh B Jani, Samuel Hellman
Apr 12, 2003·The Lancet Oncology·Richard E Peschel, John W Colberg
Mar 17, 2004·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·Ashesh B JaniCharles A Pelizzari
Jun 15, 2004·Prostate Cancer and Prostatic Diseases·L PottersM Kattan
Jan 5, 2005·International Journal of Radiation Oncology, Biology, Physics·Gregory S MerrickEdward Adamovich

❮ Previous
Next ❯

Citations

Oct 11, 2008·American Journal of Clinical Oncology·Ashesh B JaniOtis W Brawley
May 17, 2007·Prostate Cancer and Prostatic Diseases·A B JaniP A S Johnstone
Feb 6, 2007·Clinical Drug Investigation·Ashesh B JaniJeffrey M Feinstein
Aug 21, 2010·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·A Bossi
Sep 15, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Bradley R PietersAeilko H Zwinderman
Oct 29, 2009·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Carlos A S FrancaAntonio B R Penna
Jan 18, 2008·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Carlos A S FrancaAntonio B R Penna

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.